Predicted protein targets (top 3)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SIGMAR1 | Q99720 | 2/20 | 0.37 |
| ▸ | DRD2 | P14416 | 1/20 | 0.33 |
| ▸ | NEK2 | P51955 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4461573 | 0.65 | SIGMAR1 (0.39) | SIGMAR1DRD2NEK2 | |
| SCHEMBL29935626 | 0.62 | SIGMAR1 (0.37) | SIGMAR1DRD2NEK2 | |
| SCHEMBL9373229 | 0.61 | SIGMAR1 (0.36) | SIGMAR1DRD2NEK2 | |
| SCHEMBL4147170 | 0.60 | HSD17B10 (0.33) | — | |
| SCHEMBL24306877 | 0.60 | SIGMAR1 (0.35) | SIGMAR1DRD2 | |
| SCHEMBL31284236 | 0.60 | SIGMAR1 (0.34) | SIGMAR1DRD2NEK2 | |
| SCHEMBL7199450 | 0.60 | CRBN (0.34) | SIGMAR1DRD2NEK2 | |
| SCHEMBL12700561 | 0.58 | SIGMAR1 (0.33) | SIGMAR1DRD2NEK2 | |
| SCHEMBL5389801 | 0.58 | CRBN (0.37) | SIGMAR1DRD2 | |
| SCHEMBL341800 | 0.57 | NEK2 (0.33) | SIGMAR1NEK2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090054467-A1 | Pyrrolo Pyrimidines as Agents for the Inhibition of Cystein Proteases | BETSCHART CLAUDIA | 2009-02-26 | — | — | US | disclosed |
| US-7452886-B2 | Pyrrolo pyrimidines as agents for the inhibition of cystein proteases | NOVARTIS AG (CH) | 2008-11-18 | — | — | US | disclosed |
| EP-1423391-B8 | PYRROLO PYRIMIDINES AS AGENTS FOR THE INHIBITION OF CYSTEIN PROTEASES | NOVARTIS AG (CH) | 2007-12-12 | — | — | EP | disclosed |
| EP-1423391-B1 | PYRROLO PYRIMIDINES AS AGENTS FOR THE INHIBITION OF CYSTEIN PROTEASES | NOVARTIS AG (CH) | 2006-05-17 | — | — | EP | disclosed |
| US-20050054851-A1 | Pyrrolo pyrimidines as agents for the inhibition of cystein proteases | NOVARTIS AG (CH) | 2005-03-10 | — | — | US | disclosed |
| EP-1423391-A1 | PYRROLO PYRIMIDINES AS AGENTS FOR THE INHIBITION OF CYSTEIN PROTEASES | Novartis AG (CH) | 2004-06-02 | — | — | EP | disclosed |
| WO-2003020721-A1 | PYRROLO PYRIMIDINES AS AGENTS FOR THE INHIBITION OF CYSTEIN PROTEASES | NOVARTIS AG (CH) | 2003-03-13 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050054851-A1 | Pyrrolo pyrimidines as agents for the inhibition of cystein proteases | CTSK, CTSS, CTSZ | SIGMAR1 4770/4885DRD2 4870/4885NEK2 1238/4885 |
| US-20090054467-A1 | Pyrrolo Pyrimidines as Agents for the Inhibition of Cystein Proteases | CTSK, CTSS, CTSZ | SIGMAR1 4770/4885DRD2 4870/4885NEK2 1238/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.